Global InformationAzoximer bromide information
 | |
| Clinical data | |
|---|---|
| Other names | Polyoxidonium, Synpol |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | up to 89% |
| Elimination half-life | 25.4 hours (intravenous routes) |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| DrugBank |
|
| UNII |
|
| Chemical and physical data | |
| Formula | [C8H15BrN2O2]x[C6H12N2O]y]n |
| Molar mass | 60000–100000 g/mol |
Azoximer bromide, sold by the trade name Polyoxidonium by Petrovax NPO, is a water-soluble cationic polymer, adjuvant for use with the hemagglutinin glycoprotein-based influenza vaccine Grippol. Azoximer bromide is a ternary copolymer of 1,4-ethylene piperazine, 1,4-ethylene piperazine-N-oxide, and (N-carboxymethylene)-1,4-ethylene piperazinium bromide with a molecular weight of 60–100 kDa. A derivative of poly(1,4-ethylene piperazine), it is synthesized by a partial oxidation of the parent polymer with hydrogen peroxide to introduce N-oxide groups followed by the quaternization of non-oxidized amino groups with bromoacetic acid.[1][2][3]
Azoximer bromide is registered under US Patent-5503830 from 1996, and in the Russian Federation from 1996, under registration number 96/302/9, FS 42-3906-00. In Slovakia, azoximer bromide 6 mg lyophilisate for solution for injection has been authorized since 2002 for the treatment of diseases accompanied by secondary immunodeficiency in adults, including acute and recurrent infections, allergies, septic conditions, post-surgical complications and treatment-induced immune deficiency.[4]
The clinical effectiveness of azoximer bromide has not been confirmed by independent clinical studies that meet modern standards of evidence-based medicine: there are few double-blind randomized and placebo-controlled studies with a sufficient number of participants and the publication of results in well-regarded scientific journals with high impact factors.[5][6][7][8]
- ^ Powell BS, Andrianov AK, Fusco PC (January 2015). "Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes". Clinical and Experimental Vaccine Research. 4 (1): 23–45. doi:10.7774/cevr.2015.4.1.23. PMC 4313107. PMID 25648619.
- ^ Shainyan K (2004-11-08). "Оздоровление с риском для жизни" [Wellness at the risk of life]. Kommersant (in Russian). Retrieved 2021-04-03.
- ^ NPO Petrovax (2021-02-15). "A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19)".
- ^ "Detail lieku - POLYOXIDONIUM 6 mg". ŠÚKL (in Slovak).
- ^ "Azoximer Bromide". Drugs.com. Retrieved 2015-10-02.
- ^ U.S. patent 5,503,830
- ^ EP patent 0789586, "Compounds for the Prevention and Treatment of Helminth Infections"
- ^ "CLINICAL ASPECTS OF USE OF IMMUNOMODULATOR POLYOXIDONIUM". Methodical handbook for doctors issued by State Scientific Centre of Russian Federation – Immunological Institute of Russian Federation Health Resort. Moscow: State Scientific Centre of Russian federation, Immunological Institute of Russian Federation Health Resort. 2003.